Perspective Therapeutics (NASDAQ:CATX) and ReShape Lifesciences (OTCMKTS:RSLSD) Head-To-Head Analysis

ReShape Lifesciences (OTCMKTS:RSLSD) and Perspective Therapeutics (NASDAQ:CATX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability and analyst recommendations.

Profitability

This table compares ReShape Lifesciences and Perspective Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ReShape Lifesciences	-668.58%	-163.22%	-52.10%
Perspective Therapeutics	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of current ratings and recommmendations for ReShape Lifesciences and Perspective Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ReShape Lifesciences	0	0	0	0	0.00
Perspective Therapeutics	0	0	3	0	3.00

Perspective Therapeutics has a consensus price target of $10.00, suggesting a potential upside of 296.83%. Given Perspective Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Perspective Therapeutics is more favorable than ReShape Lifesciences.

Earnings and Valuation

This table compares ReShape Lifesciences and Perspective Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ReShape Lifesciences	$610,000.00	0.00	-$81.15 million	N/A	N/A
Perspective Therapeutics	N/A	N/A	N/A	($0.90)	-2.80

Perspective Therapeutics has lower revenue, but higher earnings than ReShape Lifesciences.

Institutional & Insider Ownership

54.7% of Perspective Therapeutics shares are owned by institutional investors. 3.5% of Perspective Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Risk & Volatility

ReShape Lifesciences has a beta of 2.03, meaning that its stock price is 103% more volatile than the S&P 500. Comparatively, Perspective Therapeutics has a beta of 1.22, meaning that its stock price is 22% more volatile than the S&P 500.

Summary

Perspective Therapeutics beats ReShape Lifesciences on 8 of the 10 factors compared between the two stocks.

About ReShape Lifesciences

ReShape Lifesciences Inc., a medical device company, focuses on the design, development, and commercialization of technology to treat obesity, metabolic diseases, and other gastrointestinal disorders. The company's product portfolio includes ReShape vBloc, a therapy that enables patients to feel full and eat less by intermittently blocking hunger signals on the vagus nerve; ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without permanently changing patient anatomy; and Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in October 2017. ReShape Lifesciences Inc. was founded in 2002 and is headquartered in San Clemente, California.

About Perspective Therapeutics

Isoray, Inc., through its subsidiary, IsoRay Medical, Inc., develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. Isoray, Inc. was founded in 1998 and is based in Richland, Washington.